Skip to main content
Premium Trial:

Request an Annual Quote

Biocept Prices Public Offering

NEW YORK (GenomeWeb) – Molecular diagnostics firm Biocept announced today that it has priced a public offering of approximately 5 million shares of it common stock at $1 per share.

As part of the offering, investors will also receive warrants to purchase up to roughly 3.5 million additional shares at an exercise price of $1.30 per share. The warrants are immediately exercisable and have a term of five years.

Biocept said that it expects net proceeds of $4.4 million from the offering, which will be used for working capital and general corporate purposes. HC Wainwright acted as the exclusive placement agent for the offering, and Roth Capital Partners provided advisory services.

Biocept reported having $8.8 million in cash and cash equivalents at the end of 2015. 

During mid-morning trading on the Nasdaq, shares of Biocept tumbled 21 percent, falling $.27 to $.99 a share.

The Scan

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.

New Oral Nanomedicine Strategy Targets Gut-Brain Axis to Treat IBD

A new paper in Science Advances describes a platform to design polyphenol-armored oral medicines that are effective at treating inflammatory bowel disease.

Phylogenetic Data Enables New Floristic Map

Researchers in Nature Communications use angiosperm phylogenetic data to refine the floristic regions of the world.

Machine Learning Helps ID Molecular Mechanisms of Pancreatic Islet Beta Cell Subtypes in Type 2 Diabetes

The approach helps overcome limitations of previous studies that had investigated the molecular mechanisms of pancreatic islet beta cells, the authors write in their Nature Genetics paper.